Aspira Women's Health (AWH) Investor presentation summary

Transforming gynecologic care with AI-powered diagnostics

• Leveraging data-driven, AI-powered testing to improve gynecologic care and empower patients and providers.

• Focus on innovative, non-invasive diagnostics for ovarian cancer and endometriosis.

Addressable market and product pipeline

• Over 10.5 million addressable patients for commercialized and pipeline products.

• OvaSuite targets ovarian cancer risk; ENDOinform targets endometriosis with AI-powered, multi-omic technology.

• OVAinform expands risk assessment to include germline and familial risk.

• ENDOinform and OVAinform utilize proprietary protein and miRNA biomarkers.

Clinical performance and competitive advantages

• Ova1 has >98% sensitivity with clinical assessment and >99% negative predictive value.

• Ova1 outperforms CA-125 and ROMA, especially in early-stage and diverse populations.

• OvaWatch could reduce avoidable adnexal mass surgeries by up to 62%.

• AI-enabled, multi-omic approach increases diagnostic performance in heterogeneous diseases.